Equinox Resources
Protocol for the Initiation of Hormone Therapy V2 Aug 2020
HT Prescribing Guideline V3 Aug 2020
Equinox Feminising Hormones Patient Consent and FAQ Form
Equinox Masculinising Hormones Patient Consent and FAQ Form
Equinox Evaluation Report
TGD STI Testing Services Guidance
Policy and Practice Recommendations for Alcohol and Drug Services
Thorne Harbour Health TGD training packages for health professionals
https://thorneharbour.org/services/training-and-capacity-building/tgdich/
If you are a GP or Sexual Health Physician interested in learning more about transgender health and working at Equinox, please contact Acting Director of Clinical Services, Peter Locke on peter.locke@thorneharbour.org Opportunities for clinicians who can bill Medicare GP item numbers are available at Thorne Harbour Health medical services and we are always seeking new clinicians to support our communities. Training and mentoring support is available.
Research Publications
Equinox staff and clients have contributed to and participated in the following published research. If you have any issues accessing these through the links provided, you can email the researchers at Trans Health Research gender-research@unimelb.edu.au and they will email you a copy of the article that you are interested in.
1. Relationships between body mass index with oral estradiol dose and serum estradiol concentration in transgender adults undergoing feminising hormone therapy. Ther Adv Endocrinol Metab 2020;11:1-7.
Nolan BJ, Brownhill A, Bretherton I, Wong P, Fox S, Locke P, Russell N, Grossmann M, Zajac JD, Cheung AS.
https://doi.org/10.1177/2042018820924543
2. Prevalence of polycythaemia with different formulations of testosterone therapy in transmasculine individuals. Intern Med J. 2020 Apr 1
Nolan BJ, Leemaqz SY, Ooi O, Cundill P, Silberstein N, Locke P, Grossmann M, Zajac JD, Cheung AS.
https://doi.org/10.1111/imj.14839
3. Non-Binary and Binary Gender Identity in Australian Trans and Gender Diverse Individuals. Arch Sex Behav. 2020 Apr 13.
Cheung AS, Leemaqz SY, Wong JP, Chew D, Ooi O, Zwickl S, Cundill P, Silberstein N, Locke P, Grayson R, Zajac JD, Pang KC.
https://doi.org/10.1007/s10508-020-01689-9
4. Cyproterone acetate or spironolactone in lowering testosterone concentrations for transgender individuals receiving estradiol therapy. Endocr Connect 2019; 8(7):935-940.
Angus L, Leemaqz S, Ooi O, Cundill P, Silberstein N, Locke P, Zajac JD, Cheung AS.
http://dx.doi.org/10.1530/EC-19-0272
5. Sociodemographic and Clinical Characteristics of Transgender Adults in Australia. Transgender Health 2018; 3(1), 229-238.
Cheung AS, Ooi O, Leemaqz S, Cundill P, Silberstein N, Bretherton I, Thrower E, Locke P, Grossmann M, Zajac JD.
https://doi.org/10.1089/trgh.2018.0019
6. The Informed Consent Model of Care for Accessing Gender-Affirming
Hormone Therapy Is Associated With High Patient Satisfaction.
Spanos C, Grace JA, Leemaqz SY, Brownhill A, Cundill,P, Locke P, Wong P, Zajac JD, Cheung AS.
https://authors.elsevier.com/sd/article/S1743-6095(20)30995-4
7. Gender-Affirming Hormone Therapy for the Trans, Gender Diverse, and Nonbinary Community: Coordinating World Professional Association for Transgender Health and Informed Consent Models of Care. Transgender Health 2022 Vol. 8 Issue 2 Pages 137-148 DOI:10.1089/trgh.2021.0069
Solanki P, Colon-Cabrera D, Barton C, Locke P, Cheung AS, Spanos C, Grace J, Erasmus J, and Lane R.
https://research.monash.edu/en/publications/gender-affirming-hormone-therapy-for-the-trans-gender- diverse-and
8. Early Access to Testosterone Therapy in Transgender and Gender-Diverse Adults Seeking Masculinization. A randomised Clinical Trial.
Brendan J. Nolan,MBBS1,2,3Sav Zwickl, PhD2Peter Locke3; et al
EQUINOX 